The type of ovarian cancer that is drawing researchers' attention is formally known as high-grade serous ovarian cancer, or HGSOC. Doctors also refer to it as epithelial high-grade serous ovarian ...

An NDA has been accepted by the FDA for the combination of avutometinib and defactinib in KRAS-mutated recurrent low-grade serous ovarian cancer. In the cancer world — or anywhere — the ability to ...

Some risk factors for epithelial ovarian cancer are modifiable, according to a study published online Jan. 6 in the ...

However, researchers at the Penn Ovarian Cancer Research Center at the University of Pennsylvania are studying a surprising ...

High-grade serous ovarian cancer (HGSC) is among the most lethal gynecologic malignancies, with up to 90% of patients eventually becoming resistant to platinum-based chemotherapy. The limited ...

The guideline authors used data from 61 studies to provide recommendations on the use of neoadjuvant chemotherapy in patients with newly diagnosed, stage III-IV epithelial ovarian, fallopian tube, or ...

An NDA has been accepted by the FDA for the combination of avutometinib and defactinib in KRAS-mutated recurrent low-grade serous ovarian cancer. As we near the end of 2024, CURE is looking back at ...

If approved, the combination regimen would be the first FDA-approved treatment for adults with recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC).

While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient ...

There are currently no FDA-approved treatments specifically for LGSOC, a rare and distinct ovarian cancer that differs from high-grade serous ovarian cancer in both its biology and how it responds ...